Shavit Capital

Gary Leibler, as founder and managing partner, leads the firm. The investment committee is chaired by partner Leon Recanati, and the broader partnership includes Gabriel Menaged, Jonathan Leibler, and Daniel Meron. This group collectively oversees deal evaluation and approval.

Shavit sources opportunities from within the Israeli technology ecosystem, leveraging its partners' networks and the country's dense pipeline of growth-stage private companies. Its venture partners — Asaf Iram, Neil Cohen, and Erez Yuval — extend the firm's origination reach into cross-border and sector-specific opportunities.

Shavit Capital is structured as an institutional fund manager, not a family office. It manages pooled private equity funds on behalf of external limited partners, concentrating on late-stage Israeli companies.

The firm makes direct investments into companies, typically via equity, mezzanine, or bridge rounds. It does not operate as a fund-of-funds or invest in external venture capital or private equity partnerships.

Shavit targets the pre-IPO and late-growth stage. It invests in companies with proven products and management teams that are typically within 12 to 24 months of a liquidity event, whether a Nasdaq listing or a trade sale. It does not make post-IPO secondary-market purchases.

Its portfolio historically spans medical devices (Alpha TAU), fintech (eToro Group), biopharma (Chemomab Therapeutics, Foamix Pharmaceuticals), and enterprise technology. The firm focuses on sectors where Israeli companies have demonstrated exportable innovation.

Leon Recanati serves as partner and chairman of Shavit Capital's investment committee, bringing institutional governance to the partnership. The Recanati family is well-known in Israeli business circles, but Shavit operates as an independent fund manager rather than a dedicated family investment vehicle.